Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

China Opens Order 818 Pathway; Gene and Cell Therapies Gain Fast-Track Approval Route

China has launched a new regulatory pathway that could accelerate patient access to advanced biomedical technologies while reshaping global clinical development strategies. The regulation, known as Order 818, took effect on May 1, 2026, and allows selected gene editing therapies,
  • News
China Opens Order 818 Pathway; Gene and Cell Therapies Gain Fast-Track Approval Route

Federal Funding Freeze Pressures U.S. Biotech; State Networks Rush to Stabilize R&D

Life science organizations across the United States are calling for stronger local and state-level support as federal funding delays and policy shifts intensify pressure on biotech companies. In a June 10, 2026 opinion piece, industry leader Jennifer Hawks Bland highlights
  • News
Federal Funding Freeze Pressures U.S. Biotech; State Networks Rush to Stabilize R&D

Risk Management in QMS in 2026: ICH Q9 Framework, GMP Controls, and CAPA Integration

Discover how pharmaceutical companies use ICH Q9 principles, GMP risk assessment, and CAPA integration to strengthen quality oversight, improve inspection readiness, and build effective quality risk management programs that support compliance, patient safety, and continuous improvement in 2026.
  • Blog, Quality Management System
Pharmaceutical quality professionals performing GMP risk assessment and quality risk assessment activities using the ICH Q9 risk management framework

Inside the MASH Power Shift; Rivus Forces HU6 Into High-Stakes Phase 3 Breakthrough

Rivus Pharmaceuticals enters a new development phase as CEO Jorge Bartolome outlines a shift toward late-stage clinical execution in MASH and broader cardiometabolic disease. The company advances its lead asset HU6 into Phase 3 planning while expanding its pipeline in
  • News
Inside the MASH Power Shift; Rivus Forces HU6 Into High-Stakes Phase 3 Breakthrough

Pentagon Labels WuXi AppTec Military Linked; Pharma Supply Chain Shock Intensifies

The U.S. Department of Defense has added WuXi AppTec, a Shanghai-based contract research, development, and manufacturing organization, to its list of “Chinese military companies,” according to a notice set for publication in the Federal Register on June 9, 2026. The
  • News
Pentagon Labels WuXi AppTec Military Linked; Pharma Supply Chain Shock Intensifies

QMS Implementation in 2026: GMP Compliance Failures and Regulatory Inspection Risks

This article explains how QMS Implementation in 2026 strengthens GMP inspection readiness by improving CAPA effectiveness, data integrity compliance, and change control management. It also highlights how pharmaceutical quality systems reduce FDA inspection findings and ensure regulatory compliance stability across
  • Blog, Quality Management System
Pharmaceutical quality system model showing CAPA effectiveness, data integrity compliance, and change control management aligned with GMP inspection readiness and ICH Q10 principles

70% Clinicians Untrained on AI as Hospitals Face Hidden Safety Crisis; Training Gap Exposes

AI is now saving clinicians significant time across global healthcare systems, according to a Philips Future Health Index survey published in a Reuters report on June 9, 2026. The study shows that while artificial intelligence improves efficiency and clinical capacity,
  • News
70% Clinicians Untrained on AI as Hospitals Face Hidden Safety Crisis; Training Gap Exposes

Merck and Novartis Drive Pharma Layoffs 2026; FDA Rare Disease Shift Sparks Regulatory Pressure

On June 8, 2026, the latest BioSpace layoff tracker highlights a continuing wave of workforce reductions across major pharmaceutical companies, including Merck, Novartis, Bristol Myers Squibb, Gilead Sciences, AbbVie, and Takeda. These cuts span manufacturing, R&D, and corporate functions across
  • News
Merck and Novartis Drive Pharma Layoffs 2026; FDA Rare Disease Shift Sparks Regulatory Pressure